KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Goodwill (2022 - 2025)

Halozyme Therapeutics (HALO) has disclosed Goodwill for 4 consecutive years, with $580.4 million as the latest value for Q4 2025.

  • Quarterly Goodwill rose 39.23% to $580.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $580.4 million through Dec 2025, up 39.23% year-over-year, with the annual reading at $580.4 million for FY2025, 39.23% up from the prior year.
  • Goodwill for Q4 2025 was $580.4 million at Halozyme Therapeutics, up from $416.8 million in the prior quarter.
  • The five-year high for Goodwill was $580.4 million in Q4 2025, with the low at $199.5 million in Q2 2022.
  • Average Goodwill over 4 years is $398.2 million, with a median of $416.8 million recorded in 2023.
  • The sharpest move saw Goodwill surged 108.95% in 2023, then changed 0.0% in 2024.
  • Over 4 years, Goodwill stood at $409.0 million in 2022, then rose by 1.9% to $416.8 million in 2023, then changed by 0.0% to $416.8 million in 2024, then soared by 39.23% to $580.4 million in 2025.
  • According to Business Quant data, Goodwill over the past three periods came in at $580.4 million, $416.8 million, and $416.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.